ストックスクリーナーアプリを入手
3.57
4.29%
-0.16
アフターアワーズ：
3.58
0.01
+0.28%
前日終値:
$3.73
開ける：
$3.73
24時間の取引高:
103.76K
Relative Volume:
1.51
時価総額：
$35.45M
収益：
$20.34M
当期純損益:
$-24.52M
株価収益率:
-0.9983
EPS:
-3.5761
ネットキャッシュフロー:
$-5.92M
1週間 パフォーマンス:
-8.34%
1か月 パフォーマンス:
-7.27%
6か月 パフォーマンス:
-44.22%
1年 パフォーマンス:
-38.88%
1日の値動き範囲:
$3.53
$3.915
1週間の範囲:
$3.53
$4.22
52週間の値動き範囲:
$3.53
$10.48
Scynexis Inc Stock (SCYX) Company Profile
Compare SCYX vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
3.57 | 37.04M | 20.34M | -24.52M | -5.92M | -3.5761 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-01-22 | 開始されました | Guggenheim | Buy |
| 2021-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-11 | アップグレード | Needham | Hold → Buy |
| 2018-06-27 | 開始されました | Maxim Group | Buy |
| 2017-10-24 | 開始されました | Guggenheim | Buy |
| 2017-07-10 | 開始されました | ROTH Capital | Buy |
| 2017-05-09 | ダウングレード | Needham | Buy → Hold |
| 2017-03-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-20 | 開始されました | H.C. Wainwright | Buy |
| 2016-10-07 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | 再開されました | Brean Capital | Buy |
| 2016-08-17 | 開始されました | Guggenheim | Buy |
| 2016-08-09 | 繰り返されました | Needham | Buy |
| 2016-08-09 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | 開始されました | Brean Capital | Buy |
| 2015-12-29 | 開始されました | WBB Securities | Speculative Buy |
| 2015-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-06-10 | 開始されました | Needham | Buy |
| 2014-05-29 | 開始されました | Canaccord Genuity | Buy |
| 2014-05-29 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Scynexis Inc (SCYX) 最新ニュース
SCYNEXIS Inc (SCYX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
SCYNEXIS Inc (SCYX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SCYNEXIS Inc (SCYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SCYNEXIS, Inc. Revenue Breakdown – NASDAQ:SCYX - TradingView
SCYNEXIS, Inc. Revenue Breakdown – LSE:0L49 - TradingView
SCYNEXIS Inc (SCYX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SCYNEXIS (SCYX) Slides 2.35% as Biotech Stock Tests Key Support LevelInsider Buying Alerts - dars.gov.et
Federated Hermes (SCYX) group discloses 4.03% Scynexis stake in amended 13G - Stock Titan
FEDERATED HERMES, INC. Acquires 55,207 Shares of SCYNEXIS Inc - GuruFocus
Federated Hermes (SCYX) files 13G/A showing 55,207 shares (4.45%) - Stock Titan
Scynexis Deadline Alert - TMX Newsfile
Enterprise value to EBIT forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Enterprise value to EBIT forward of SCYNEXIS, Inc. – FWB:135 - TradingView
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
SCYNEXIS (NASDAQ:SCYX) Is In A Strong Position To Grow Its Business - Sahm
Form DEF 14A Scynexis Inc For: 2 July By Investing.com - Investing.com Nigeria
Scynexis: Buy Rating Reiterated as Rare Disease Pipeline Advances; $32 Price Target Maintained - TipRanks
Form 4 Scynexis Inc For: 30 June By Investing.com - Investing.com Nigeria
SCYNEXIS (SCYX) director receives new RSU and stock option grants - Stock Titan
SCYNEXIS (NASDAQ: SCYX) director gets RSU and option awards - Stock Titan
SCYNEXIS (SCYX) director Armando Anido granted stock units and options - Stock Titan
SCYNEXIS (SCYX) director receives new stock and option awards - Stock Titan
SCYNEXIS (SCYX) director Ann Hanham receives stock and option grants - Stock Titan
Enterprise value to revenue forward of SCYNEXIS, Inc. – FWB:135 - TradingView
Scynexis (SCYX) Launches Phase 1 Study for SCY-770 in Kidney Dis - GuruFocus
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - The Manila Times
SCYNEXIS Inc. (SCYX) Q1 2026 Earnings: Wider-than-Expected Loss on No Reported Revenue; Stock Rises 5.17%EBITDA Analysis - dars.gov.et
Enterprise value to revenue forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Enterprise value to revenue forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Price to book forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Price to earnings forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Price to sales forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Price to book forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Enterprise value to EBITDA forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Price to sales forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Enterprise value to EBITDA forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
SCYNEXIS (SCYX) Edges Higher as Support Holds, Resistance AwaitsRetracement Entry - dars.gov.et
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes - TipRanks
SCYNEXIS (SCYX) expands authorized stock and registers 87M shares for resale - Stock Titan
SCYNEXIS Inc (SCYX) Valuation: PE, PB & Fair Value Analysis - TradingKey
SCYNEXIS, Inc. Actuals & Estimates (NASDAQ:SCYX) - TradingView
SCYX Forecast — Price Target — Prediction for 2027 - TradingView
SCYNEXis (SCYX) Surges 6.6% – Testing Key Resistance at $4.25Low Beta Factor - dars.gov.et
SCYNEXIS Inc (SCYX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SCYNEXIS Inc (SCYX) Institutional Confidence - TradingKey
SCYNEXIS Inc (SCYX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SCYNEXIS Inc (SCYX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SCYNEXIS (SCYX) Holds Near Support Amid Quiet TradingFast Moving Stocks - newsline.com
SCYNEXIS Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueEPS Revision Trend - dars.gov.et
SCYNEXIS, Inc. Hits New 52-Week High of $5.62, Up 157.49% - MarketsMojo
Scynexis Inc (SCYX) 財務データ
収益
当期純利益
現金流量
EPS
0.30%
2.01%
大文字化:
|
ボリューム (24 時間):